Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ballantyne

Showing results (81-90 of 999) with videos related to

Pageof 100
Sort By:
Molecular and Cellular Biology|March 1, 1991
Meiotic induction by Xenopus cyclin B is accelerated by coexpression with mosXeR S Freeman, S M Ballantyne, D J Donoghue
Applied Optics|February 4, 2010
Properties of a Light-Modified-Breakdown Detector in GaAsJ M Ballantyne, J P Baukus, J M Lavin
The Analyst|April 22, 2009
Linker immobilization of protein and oligonucleotide on indium-tin-oxide for detection of probe-target interactions by Kelvin physicsMarwan Saoud, Christophe Blaszykowski, Scott M Ballantyne, et al.
Journal of Lipid Research|April 7, 2009
Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities StudyKeri L Monda, Christie M Ballantyne, Kari E North
Journal of the American College of Cardiology|August 16, 2008
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trialChristie M Ballantyne, Joel S Raichlen, Valerie A Cain
Current Opinion in Endocrinology, Diabetes, and Obesity|January 4, 2021
Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pondAli M Agha, Salim S Virani, Christie M Ballantyne
Current Atherosclerosis Reports|April 1, 2021
How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?Trevor D Hadley, Ali M Agha, Christie M Ballantyne
Current Cardiology Reports|July 16, 2021
Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?Matthew R Deshotels, Salim S Virani, Christie M Ballantyne
European Heart Journal|March 20, 2013
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugsGiuseppe Danilo Norata, Christie M Ballantyne, Alberico Luigi Catapano
The American Journal of Cardiology|June 6, 2015
Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus FactsJoshua W Knowles, Neil J Stone, Christie M Ballantyne
Pageof 100

Showing results (81-90 of 999) with videos related to

Sort By:
Pageof 100
Molecular and Cellular Biology|March 1, 1991
Meiotic induction by Xenopus cyclin B is accelerated by coexpression with mosXeR S Freeman, S M Ballantyne, D J Donoghue
Applied Optics|February 4, 2010
Properties of a Light-Modified-Breakdown Detector in GaAsJ M Ballantyne, J P Baukus, J M Lavin
The Analyst|April 22, 2009
Linker immobilization of protein and oligonucleotide on indium-tin-oxide for detection of probe-target interactions by Kelvin physicsMarwan Saoud, Christophe Blaszykowski, Scott M Ballantyne, et al.
Journal of Lipid Research|April 7, 2009
Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities StudyKeri L Monda, Christie M Ballantyne, Kari E North
Journal of the American College of Cardiology|August 16, 2008
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trialChristie M Ballantyne, Joel S Raichlen, Valerie A Cain
Current Opinion in Endocrinology, Diabetes, and Obesity|January 4, 2021
Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pondAli M Agha, Salim S Virani, Christie M Ballantyne
Current Atherosclerosis Reports|April 1, 2021
How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?Trevor D Hadley, Ali M Agha, Christie M Ballantyne
Current Cardiology Reports|July 16, 2021
Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?Matthew R Deshotels, Salim S Virani, Christie M Ballantyne
European Heart Journal|March 20, 2013
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugsGiuseppe Danilo Norata, Christie M Ballantyne, Alberico Luigi Catapano
The American Journal of Cardiology|June 6, 2015
Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus FactsJoshua W Knowles, Neil J Stone, Christie M Ballantyne
Pageof 100